Valentina N. Dvirnyk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Valentina N. Dvirnyk has a total of 262 co-authors. Here are the top co-authors by number of shared publications:
- Elena Parovichnikova
National Medical Research Center of Hematology
28 shared publications - Irina Vladimirovna Galtseva
National Medical Research Center for Hematology, 125167 Moscow, Russia
17 shared publications - Vera V. Troitskaya
National Medical Research Center for Hematology, Ministry of Health of Russia
17 shared publications - Alla Mikhailovna Kovrigina
National Medical Research Center for Hematology
16 shared publications - Andrey Borisovich Sudarikov
National Medical Research Center for Hematology, 125167 Moscow, Russia
15 shared publications - Tatiana N. Obukhova
National Medical Research Center for Hematology, 125167 Moscow, Russia
15 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (2) , 258-270
Platelet hemostatic disorders: how to reach a diagnosis?
Introduction . Thrombocytopenia can be primary or secondary and warrants differential diagnosis of hereditary functional platelet defects. Aim : to present the difficulties of verifying the diagnosis in disorders of the platelet component of hemostasis. Main findings. A clinical case of a 28-year old female patient is presented. The patient presented with a mild mucocutaneous hemorrhagic syndrome and moderate thrombocytopenia of a familial nature. All available routine and alternative methods for investigating platelet disorders were performed. Whole genome sequencing proved to be a crucial diagnostic method. This genetic analysis, in comparison with morphological and functional studies, is a promising tool for the differential diagnosis of heterogeneous platelet disorders.
- 17 July 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (2) , 258-270
Open AccessPlatelet hemostatic disorders: how to reach a diagnosis?
Introduction . Thrombocytopenia can be primary or secondary and warrants differential diagnosis of hereditary functional platelet defects. Aim : to present the difficulties of verifying the diagnosis in disorders of the platelet component of hemostasis. Main findings. A clinical case of a 28-year old female patient is presented. The patient presented with a mild mucocutaneous hemorrhagic syndrome and moderate thrombocytopenia of a familial nature. All available routine and alternative methods for investigating platelet disorders were performed. Whole genome sequencing proved to be a crucial diagnostic method. This genetic analysis, in comparison with morphological and functional studies, is a promising tool for the differential diagnosis of heterogeneous platelet disorders.
- Open Access
- 23 March 2026
- Published by Publishing House ABV Press in Oncohematology
- Vol. 21 (1)
Characteristics and dynamics of the residual tumor clone determined by multicolor flow cytometry in Waldenstrom’s macroglobulinemia
Background. Minimal residual disease (MRD), as determined by immunophenotyping, is an indicator of therapy response and a marker of relapse in many hematological diseases. There are some foreign publications devoted to the assessment of the residual tumor population using multicolor flow cytometry in Waldenstrom’s macroglobulinemia (WM). A characteristic feature of WM is the infiltration of bone marrow by two tumor populations from one tumor clone: clonal B-lymphocytes and clonal plasma cells. The study of these two aberrant populations was only possible using flow cytometry. In 90 % of WM cases, the L265P mutation of the MYD88 gene is detected: it is a diagnostic marker and is much less common in other lymphomas. Aim. To investigate the residual tumor clone characteristics in WM patients, their correlation with progression, assess the relationship between the monoclonal immunoglobulin M dynamics and MRD status, as well as between the presence of the MYD88 mutation at onset and the rate of tumor clone reduction. Materials and methods. Patients underwent immunophenotypic analysis of bone marrow cells at disease onset and at follow-up time points post-induction using multicolor flow cytometry. The following antigens were investigated for B-cells: surface CD19, CD22, CD20, CD45, and CD27, as well as cytoplasmic λ and κ immunoglobulin M antigens. For plasma cells, the following were assessed: surface CD38, CD138, CD27, CD45, CD81, and CD19, along with cytoplasmic λ and κ immunoglobulin M antigens. Standard methods of descriptive statistics and graphical visualization were used to analyze the results. To evaluate the dynamics of aberrant cell populations, multivariate statistical methods were employed, accounting for repeated measures within the same participants. The same methods were applied to study the association of the MYD88 gene mutation with the dynamics of these parameters. Results. Heterogeneity of the residual tumor clone was revealed, which could be represented by three variants of tumor populations: only aberrant B cells; only aberrant plasma cells; and populations of B- and plasma cells. Different reduction rates of residual aberrant B- and plasma cells were observed after the end of induction therapy: in the 1st month after treatment, the number of aberrant B cells decreased 1.4 times faster than plasma cells. The long-term persistence phenomenon of trace immunoglobulin M secretion after induction therapy even in MRD-negative patients was revealed (70 % cases). A relationship was noted between the presence of L265P mutation of the MYD88 gene at the disease onset and the number of residual B cells. In patients without a MYD88 gene mutation at the disease onset, MRD-negative B-cell status was achieved by the first month after the end of induction. No relationship was found between the presence / absence of the MYD88 gene mutation and the residual tumor plasma cell population. Patients with MRD-positive status in any combination (only aberrant B cells; only aberrant plasma cells; and populations of B- and plasma cells) demonstrated a higher probability of disease progression compared to the MRD-negative group. Conclusion. The use of multicolor flow cytometry to detect residual neoplastic B-cell and plasma cell populations provides additional insights into the depth of remission, the rate of tumor cell reduction, and the heterogeneity of the residual malignant clone.
- 23 March 2026
- Published by Publishing House ABV Press in Oncohematology
- Vol. 21 (1)
Open AccessCharacteristics and dynamics of the residual tumor clone determined by multicolor flow cytometry in Waldenstrom’s macroglobulinemia
Background. Minimal residual disease (MRD), as determined by immunophenotyping, is an indicator of therapy response and a marker of relapse in many hematological diseases. There are some foreign publications devoted to the assessment of the residual tumor population using multicolor flow cytometry in Waldenstrom’s macroglobulinemia (WM). A characteristic feature of WM is the infiltration of bone marrow by two tumor populations from one tumor clone: clonal B-lymphocytes and clonal plasma cells. The study of these two aberrant populations was only possible using flow cytometry. In 90 % of WM cases, the L265P mutation of the MYD88 gene is detected: it is a diagnostic marker and is much less common in other lymphomas. Aim. To investigate the residual tumor clone characteristics in WM patients, their correlation with progression, assess the relationship between the monoclonal immunoglobulin M dynamics and MRD status, as well as between the presence of the MYD88 mutation at onset and the rate of tumor clone reduction. Materials and methods. Patients underwent immunophenotypic analysis of bone marrow cells at disease onset and at follow-up time points post-induction using multicolor flow cytometry. The following antigens were investigated for B-cells: surface CD19, CD22, CD20, CD45, and CD27, as well as cytoplasmic λ and κ immunoglobulin M antigens. For plasma cells, the following were assessed: surface CD38, CD138, CD27, CD45, CD81, and CD19, along with cytoplasmic λ and κ immunoglobulin M antigens. Standard methods of descriptive statistics and graphical visualization were used to analyze the results. To evaluate the dynamics of aberrant cell populations, multivariate statistical methods were employed, accounting for repeated measures within the same participants. The same methods were applied to study the association of the MYD88 gene mutation with the dynamics of these parameters. Results. Heterogeneity of the residual tumor clone was revealed, which could be represented by three variants of tumor populations: only aberrant B cells; only aberrant plasma cells; and populations of B- and plasma cells. Different reduction rates of residual aberrant B- and plasma cells were observed after the end of induction therapy: in the 1st month after treatment, the number of aberrant B cells decreased 1.4 times faster than plasma cells. The long-term persistence phenomenon of trace immunoglobulin M secretion after induction therapy even in MRD-negative patients was revealed (70 % cases). A relationship was noted between the presence of L265P mutation of the MYD88 gene at the disease onset and the number of residual B cells. In patients without a MYD88 gene mutation at the disease onset, MRD-negative B-cell status was achieved by the first month after the end of induction. No relationship was found between the presence / absence of the MYD88 gene mutation and the residual tumor plasma cell population. Patients with MRD-positive status in any combination (only aberrant B cells; only aberrant plasma cells; and populations of B- and plasma cells) demonstrated a higher probability of disease progression compared to the MRD-negative group. Conclusion. The use of multicolor flow cytometry to detect residual neoplastic B-cell and plasma cell populations provides additional insights into the depth of remission, the rate of tumor cell reduction, and the heterogeneity of the residual malignant clone.
- Open Access
- 21 December 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (4) , 441-454
Analysis of reference intervals of myelogram parameters used in the healthcare organizations of the Russian Federation
Introduction. Cytological examination of bone marrow aspirate is a fundamental tool in the diagnosis of hematological diseases. The reference intervals for myelogram parameters serve as the primary guide for interpreting and assessing changes in the cellular elements of bone marrow. However, the reference intervals vary in the myelogram report forms of different healthcare organizations (HCOs). Aim. To analyze the reference values of myelograms used in “anchor” HCOs of the constituent entities of the Russian Federation. Materials and methods . An analysis of the reference intervals for myelogram parameters used in the “anchor” HCOs of 83 constituent entities of the Russian Federation was conducted using standard methods of descriptive statistics, expert ranking, and assessment. Results. Significant differences were identified in myelogram parameters considered as normal across different constituent entities of the Russian Federation. Reference values for myelogram parameters were absent in 1 (1.2 %) HCOs. Only 4 (4.8 %) HCOs specified the sources of their reference intervals. The remaining 78 HCOs used reference intervals from unknown sources. The analysis revealed significant disparities in the myelogram parameters accepted as normal. The upper limit for neutrophilic myelocytes varied from 10.0 % to 16.9 %, for lymphocytes from 10 % to 23.7 %, and for erythrokaryocytes from 25.0 % to 32.5 %. The permissible values for the count of blast cells in the myelogram also varied. The upper threshold for a normal blast cell count was considered ≥5 % in 7 HCOs and Conclusion. The lack of uniform, generally accepted normal myelogram parameters complicates the diagnosis and interpretation of laboratory test results by clinicians. This article provides a brief historical overview and recommendations for standardizing reference intervals for myelogram parameters.
- 21 December 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (4) , 441-454
Open AccessAnalysis of reference intervals of myelogram parameters used in the healthcare organizations of the Russian Federation
Introduction. Cytological examination of bone marrow aspirate is a fundamental tool in the diagnosis of hematological diseases. The reference intervals for myelogram parameters serve as the primary guide for interpreting and assessing changes in the cellular elements of bone marrow. However, the reference intervals vary in the myelogram report forms of different healthcare organizations (HCOs). Aim. To analyze the reference values of myelograms used in “anchor” HCOs of the constituent entities of the Russian Federation. Materials and methods . An analysis of the reference intervals for myelogram parameters used in the “anchor” HCOs of 83 constituent entities of the Russian Federation was conducted using standard methods of descriptive statistics, expert ranking, and assessment. Results. Significant differences were identified in myelogram parameters considered as normal across different constituent entities of the Russian Federation. Reference values for myelogram parameters were absent in 1 (1.2 %) HCOs. Only 4 (4.8 %) HCOs specified the sources of their reference intervals. The remaining 78 HCOs used reference intervals from unknown sources. The analysis revealed significant disparities in the myelogram parameters accepted as normal. The upper limit for neutrophilic myelocytes varied from 10.0 % to 16.9 %, for lymphocytes from 10 % to 23.7 %, and for erythrokaryocytes from 25.0 % to 32.5 %. The permissible values for the count of blast cells in the myelogram also varied. The upper threshold for a normal blast cell count was considered ≥5 % in 7 HCOs and Conclusion. The lack of uniform, generally accepted normal myelogram parameters complicates the diagnosis and interpretation of laboratory test results by clinicians. This article provides a brief historical overview and recommendations for standardizing reference intervals for myelogram parameters.
- Open Access
- 10 December 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (4) , 32-40
The significance of CD20 expression in adult patients with BCR::ABL1-negative acute B-cell lymphoblastic leukemia treated according to RALL-2016 protocol
Background. Current approaches to the treating BCR::ABL1-negative B-cell lymphoblastic leukemia (B-ALL) patients are aimed at incorporating targeted agents into chemotherapy regimens to improve the efficacy of the first-line therapy. Rituximab was one of the first such drugs to be used and shown to improve survival in B-cell lymphoproliferative disorders. Its inclusion in treatment regimens for BCR::ABL1-negative B-ALL remains controversial. Aim. To determine the prognostic value of CD20 expression on tumor cells in adult patients with BCR::ABL1-negative B-ALL treated according to the ALL-2016 protocol. Materials and methods. The study included 143 patients with BCR::ABL1-negative B-ALL who received treatment from December 2016 to February 2024 as part of the multicenter RALL-2016 trial (ClinicalTrials.gov, NCT03462095). The median patient age was 30 (18–55) years, with a male: female ratio of 71 (50 %):72 (50 %). Immunophenotyping of bone marrow blast cells using flow cytometry was performed in all patients at the disease onset. The presence of the CD20 marker on tumor cells was considered positive if its expression was ≥20 %. From September 2024 to September 2025, four patients received treatment according to the R-RALL-2016m protocol (ALL-2016m including rituximab). Results. In the RALL-2016 study, the frequency of CD20 expression in BCR::ABL1-negative B-ALL was 37 % (53 of 143). Five-year overall survival in BCR::ABL1-negative B-ALL with CD20 expression was 73 %, compared to 68 % in patients negative for this marker (p = 0.9405). Three-year relapse-free survival was 73 and 70 % in the presence and absence of CD20 expression, respectively (p = 0.7944). All patients (4 of 4) achieved bone marrow remission after phase I induction therapy according to the R-RALL-2016m protocol, and 75 % achieved negative minimal residual disease status at the end of induction therapy. Conclusion. In adult patients with BCR::ABL1-negative B-ALL, the inclusion of rituximab may improve long-term survival outcomes by more rapidly achieving clinical and hematological remission and increasing the rate of minimal residual disease negativity after induction therapy. Continued follow-up of patients receiving the new protocol is needed to assess the likelihood of late complications and long-term outcomes.
- 10 December 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (4) , 32-40
Open AccessThe significance of CD20 expression in adult patients with BCR::ABL1-negative acute B-cell lymphoblastic leukemia treated according to RALL-2016 protocol
Background. Current approaches to the treating BCR::ABL1-negative B-cell lymphoblastic leukemia (B-ALL) patients are aimed at incorporating targeted agents into chemotherapy regimens to improve the efficacy of the first-line therapy. Rituximab was one of the first such drugs to be used and shown to improve survival in B-cell lymphoproliferative disorders. Its inclusion in treatment regimens for BCR::ABL1-negative B-ALL remains controversial. Aim. To determine the prognostic value of CD20 expression on tumor cells in adult patients with BCR::ABL1-negative B-ALL treated according to the ALL-2016 protocol. Materials and methods. The study included 143 patients with BCR::ABL1-negative B-ALL who received treatment from December 2016 to February 2024 as part of the multicenter RALL-2016 trial (ClinicalTrials.gov, NCT03462095). The median patient age was 30 (18–55) years, with a male: female ratio of 71 (50 %):72 (50 %). Immunophenotyping of bone marrow blast cells using flow cytometry was performed in all patients at the disease onset. The presence of the CD20 marker on tumor cells was considered positive if its expression was ≥20 %. From September 2024 to September 2025, four patients received treatment according to the R-RALL-2016m protocol (ALL-2016m including rituximab). Results. In the RALL-2016 study, the frequency of CD20 expression in BCR::ABL1-negative B-ALL was 37 % (53 of 143). Five-year overall survival in BCR::ABL1-negative B-ALL with CD20 expression was 73 %, compared to 68 % in patients negative for this marker (p = 0.9405). Three-year relapse-free survival was 73 and 70 % in the presence and absence of CD20 expression, respectively (p = 0.7944). All patients (4 of 4) achieved bone marrow remission after phase I induction therapy according to the R-RALL-2016m protocol, and 75 % achieved negative minimal residual disease status at the end of induction therapy. Conclusion. In adult patients with BCR::ABL1-negative B-ALL, the inclusion of rituximab may improve long-term survival outcomes by more rapidly achieving clinical and hematological remission and increasing the rate of minimal residual disease negativity after induction therapy. Continued follow-up of patients receiving the new protocol is needed to assess the likelihood of late complications and long-term outcomes.
- Open Access
- 13 March 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (1) , 114-127
Interlaboratory consensus on the immunophenotypic diagnosis of chronic lymphocytic leukemia: Recommendations for the preparation of cytometric study reports and the selection of panels of monoclonal antibodies
Introduction. Immunophenotyping is a key diagnostic method for chronic lymphocytic leukemia (CLL), the most common lymphoproliferative disorder (LPD) in middle-aged and elderly individuals. Given the high prevalence of CLL, there is a need to standardize approaches to its immunophenotypic diagnosis, including the development of standardized panels of monoclonal antibodies, recommendations for sample preparation, and the formulation of reports to improve diagnostic accuracy.Aim: to develop a unified laboratory report form and a standardized approach to using the necessary and sufficient combination of labeled monoclonal antibodies for the diagnosis of CLL.Main findings. An All-Russian working group was formed under the National Hematological Society (NHS) to discuss key issues in the laboratory diagnosis of CLL. The primary focus was on problems related to immunophenotyping. Consensus decisions were made regarding the creation of a unified laboratory report form and a standardized approach to using the necessary and sufficient combination of labeled monoclonal antibodies for the diagnosis of CLL. The monoclonal antibody panel should include antibodies detecting CD19, CD20, CD5, CD23, and surface immunoglobulin light chains (k and λ). To differentiate CLL from other B-LPDs, additional markers such as CD43, CD200, CD10, CD22, and CD38 are recommended. The report form should include, along with patient information and sample type, the following: a list of used monoclonal antibodies, the flow cytometer model, the count of leukocytes and lymphocytes, the immunophenotype of the identified tumor population with emphasis on aberrant markers, the absolute count of pathological clone cells, and the final immunophenotypic variant of CLL or B-LPD.
- 13 March 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (1) , 114-127
Open AccessInterlaboratory consensus on the immunophenotypic diagnosis of chronic lymphocytic leukemia: Recommendations for the preparation of cytometric study reports and the selection of panels of monoclonal antibodies
Introduction. Immunophenotyping is a key diagnostic method for chronic lymphocytic leukemia (CLL), the most common lymphoproliferative disorder (LPD) in middle-aged and elderly individuals. Given the high prevalence of CLL, there is a need to standardize approaches to its immunophenotypic diagnosis, including the development of standardized panels of monoclonal antibodies, recommendations for sample preparation, and the formulation of reports to improve diagnostic accuracy.Aim: to develop a unified laboratory report form and a standardized approach to using the necessary and sufficient combination of labeled monoclonal antibodies for the diagnosis of CLL.Main findings. An All-Russian working group was formed under the National Hematological Society (NHS) to discuss key issues in the laboratory diagnosis of CLL. The primary focus was on problems related to immunophenotyping. Consensus decisions were made regarding the creation of a unified laboratory report form and a standardized approach to using the necessary and sufficient combination of labeled monoclonal antibodies for the diagnosis of CLL. The monoclonal antibody panel should include antibodies detecting CD19, CD20, CD5, CD23, and surface immunoglobulin light chains (k and λ). To differentiate CLL from other B-LPDs, additional markers such as CD43, CD200, CD10, CD22, and CD38 are recommended. The report form should include, along with patient information and sample type, the following: a list of used monoclonal antibodies, the flow cytometer model, the count of leukocytes and lymphocytes, the immunophenotype of the identified tumor population with emphasis on aberrant markers, the absolute count of pathological clone cells, and the final immunophenotypic variant of CLL or B-LPD.
- Open Access
- 27 December 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (12) , 1144-1150
Endothelial dysfunction in patients with systemic AL amyloidosis
Background. Research related to the state of blood vessels in systemic AL amyloidosis (AL-A) is mostly done on experimental models. The pathogenetic and clinical significance of vascular dysfunction in patients with AL-A is poorly understood. Aim. To study the levels of endothelial dysfunction markers in patients with AL-A at the onset of the disease and after anti-tumor therapy. Materials and methods. The study group included 30 patients with AL-A. The comparison group consisted of 10 patients with multiple myeloma (MM), and the control group included 10 healthy individuals. Patients with AL-A were divided into 2 groups: the first group included 20 patients who underwent the full planned induction therapy, and the second group included 10 patients whose treatment was stopped due to a significant increase in N-terminal pro-brain natriuretic peptide (NTproBNP) levels. The levels of asymmetric dimethylarginine (ADMA), big endothelin (bET), and E-selectin were measured by enzyme-linked immunosorbent assay in serum before and after completion (or premature cessation) of anti-tumor therapy. Results. Patients with AL-A had significantly higher levels of E-selectin and ADMA in serum compared to patients with MM and healthy individuals. An increase in at least one marker of endothelial dysfunction (E-selectin and ADMA) was observed in 27 (90%) patients with AL-A at disease onset. There were no differences in bET levels. In all patients in the first group, reaching hematologic remission was associated with a decrease in E-selectin and ADMA levels compared to baseline values (p0.001). In 5 (55%) out of 9 patients with hematologic and organ response, ADMA levels decreased to normal values. In all patients of the second group, the increase in NTproBNP was accompanied by a significant increase in ADMA (p=0.005) and E-selectin (p=0.007) levels compared to baseline values. Adverse cardiovascular events were observed in 80% of patients with elevated NTproBNP levels. The increase in cardiac markers during anti-tumor therapy was more common in advanced stages of heart involvement. Stage IIIA AL-A was present in 23% of patients in the first group and 70% in the second group (p=0.003). After discontinuation of therapy, the levels of cardiac markers decreased to baseline values, which ruled out disease progression. Conclusion. A pronounced endothelial dysfunction was observed in 90% of patients with AL-A. Reduction in endothelial dysfunction markers was observed upon achieving hematologic and organ response. Anti-tumor therapy in patients with amyloid cardiomyopathy can cause additional endothelial damage, resulting in increased NTproBNP levels and cardiovascular complications.
- 27 December 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (12) , 1144-1150
Open AccessEndothelial dysfunction in patients with systemic AL amyloidosis
Background. Research related to the state of blood vessels in systemic AL amyloidosis (AL-A) is mostly done on experimental models. The pathogenetic and clinical significance of vascular dysfunction in patients with AL-A is poorly understood. Aim. To study the levels of endothelial dysfunction markers in patients with AL-A at the onset of the disease and after anti-tumor therapy. Materials and methods. The study group included 30 patients with AL-A. The comparison group consisted of 10 patients with multiple myeloma (MM), and the control group included 10 healthy individuals. Patients with AL-A were divided into 2 groups: the first group included 20 patients who underwent the full planned induction therapy, and the second group included 10 patients whose treatment was stopped due to a significant increase in N-terminal pro-brain natriuretic peptide (NTproBNP) levels. The levels of asymmetric dimethylarginine (ADMA), big endothelin (bET), and E-selectin were measured by enzyme-linked immunosorbent assay in serum before and after completion (or premature cessation) of anti-tumor therapy. Results. Patients with AL-A had significantly higher levels of E-selectin and ADMA in serum compared to patients with MM and healthy individuals. An increase in at least one marker of endothelial dysfunction (E-selectin and ADMA) was observed in 27 (90%) patients with AL-A at disease onset. There were no differences in bET levels. In all patients in the first group, reaching hematologic remission was associated with a decrease in E-selectin and ADMA levels compared to baseline values (p0.001). In 5 (55%) out of 9 patients with hematologic and organ response, ADMA levels decreased to normal values. In all patients of the second group, the increase in NTproBNP was accompanied by a significant increase in ADMA (p=0.005) and E-selectin (p=0.007) levels compared to baseline values. Adverse cardiovascular events were observed in 80% of patients with elevated NTproBNP levels. The increase in cardiac markers during anti-tumor therapy was more common in advanced stages of heart involvement. Stage IIIA AL-A was present in 23% of patients in the first group and 70% in the second group (p=0.003). After discontinuation of therapy, the levels of cardiac markers decreased to baseline values, which ruled out disease progression. Conclusion. A pronounced endothelial dysfunction was observed in 90% of patients with AL-A. Reduction in endothelial dysfunction markers was observed upon achieving hematologic and organ response. Anti-tumor therapy in patients with amyloid cardiomyopathy can cause additional endothelial damage, resulting in increased NTproBNP levels and cardiovascular complications.
- Open Access
- 27 December 2024
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 69 (4) , 392-409
Multicenter randomized controlled (comparative) open prospective study to evaluate the efficacy of the R-DA-EPOCH-21 and R-mNHL-BFM-90 with and without autologous hematopoietic stem cell transplantation programs in untreated patients with de novo diffuse B-cell large cell lymphoma with signs of poor prognosis (final results)
Introduction. The R-NHL-BFM-90 protocol has been successfully used for the treatment of Burkitt’s lymphoma and diffuse large B-cell lymphoma (DLBCL) in children and adolescents, as well as adult T-cell lymphomas. The protocol was modified for the treatment of adult patients with de novo nodal DLBCL.Aim: to evaluate the efficacy and toxicity of the R-mNHL-BFM-90 and R-DA-EPOCH-21 protocols in adult patients with de novo nodal DLBCL with 2 or more signs of poor prognosis, as well as to determine the role of auto-HSCT in the consolidation of remission.Materials and methods. From 2015 to 2021, 164 patients were evaluated for randomization. The study included 140 patients from 13 Russian medical centers. 89 (76 %) patients with de novo nodal DLBCL: R-DAEPOCH-21 20 (22.5 %) patients; R-DAEPOCH-21 + auto-HSCT 21 (23.5 %) patients; R-mNHL-BFM-90 20 (22.5 %) patients; R-mNHL-BFM-90 performed + auto-HSCT 28 (31.5 %) patients. In the high-intermediate and high-risk group, there were 12 (29.3 %) and 29 (70.7 %) patients on the R-DA-EPOCH-21 + auto-HSCT protocol and 15 (31.2 %) and 32 (66.7 %) on the R-mNHL-BFM-90 protocol + auto-HSCT, respectively.Results. The R-mNHL-BFM-90 protocol proved to be more effective. Complete remission in the high-risk group was achieved in 30 (93.7 %) patients versus 18 (62.0 %), there was no progression versus 3 (10.3 %) patients treated according to R-DA-EPOCH-21 (p = 0.0167). The five-year overall and event-free survival in the high-risk group was 97 % vs. 75 % (p = 0.01) and 97 % vs. 72 % (p = 0.0026), respectively. In the intermediate risk group, the results of therapy did not differ. The toxicity of the R-mNHL-BFM-90 protocol exceeded the toxicity of R-DA-EPOCH-21 only in neutropenic fever (p = 0.04) and grade 3–4 thrombocytopenia (p = 0.0009).Conclusion. The R-mNHL-BFM-90 protocol is effective for the treatment of patients with nodal de novo DLBCL diffuse large B-cell lymphoma of high-risk adults; its toxicity is acceptable. However, on the R-DA-EPOCH-21 therapy, the results of therapy are unsatisfactory. The R-DA-EPOCH-21 protocol with auto-HSCT was more effective than without auto-HSCT, however, due to the small number of patients, the results were unpresentative. The results of therapy according R-mNHL-BFM-90 protocol with auto-HSCT and without auto-HSCT were not differ.
- 27 December 2024
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 69 (4) , 392-409
Open AccessMulticenter randomized controlled (comparative) open prospective study to evaluate the efficacy of the R-DA-EPOCH-21 and R-mNHL-BFM-90 with and without autologous hematopoietic stem cell transplantation programs in untreated patients with de novo diffuse B-cell large cell lymphoma with signs of poor prognosis (final results)
Introduction. The R-NHL-BFM-90 protocol has been successfully used for the treatment of Burkitt’s lymphoma and diffuse large B-cell lymphoma (DLBCL) in children and adolescents, as well as adult T-cell lymphomas. The protocol was modified for the treatment of adult patients with de novo nodal DLBCL.Aim: to evaluate the efficacy and toxicity of the R-mNHL-BFM-90 and R-DA-EPOCH-21 protocols in adult patients with de novo nodal DLBCL with 2 or more signs of poor prognosis, as well as to determine the role of auto-HSCT in the consolidation of remission.Materials and methods. From 2015 to 2021, 164 patients were evaluated for randomization. The study included 140 patients from 13 Russian medical centers. 89 (76 %) patients with de novo nodal DLBCL: R-DAEPOCH-21 20 (22.5 %) patients; R-DAEPOCH-21 + auto-HSCT 21 (23.5 %) patients; R-mNHL-BFM-90 20 (22.5 %) patients; R-mNHL-BFM-90 performed + auto-HSCT 28 (31.5 %) patients. In the high-intermediate and high-risk group, there were 12 (29.3 %) and 29 (70.7 %) patients on the R-DA-EPOCH-21 + auto-HSCT protocol and 15 (31.2 %) and 32 (66.7 %) on the R-mNHL-BFM-90 protocol + auto-HSCT, respectively.Results. The R-mNHL-BFM-90 protocol proved to be more effective. Complete remission in the high-risk group was achieved in 30 (93.7 %) patients versus 18 (62.0 %), there was no progression versus 3 (10.3 %) patients treated according to R-DA-EPOCH-21 (p = 0.0167). The five-year overall and event-free survival in the high-risk group was 97 % vs. 75 % (p = 0.01) and 97 % vs. 72 % (p = 0.0026), respectively. In the intermediate risk group, the results of therapy did not differ. The toxicity of the R-mNHL-BFM-90 protocol exceeded the toxicity of R-DA-EPOCH-21 only in neutropenic fever (p = 0.04) and grade 3–4 thrombocytopenia (p = 0.0009).Conclusion. The R-mNHL-BFM-90 protocol is effective for the treatment of patients with nodal de novo DLBCL diffuse large B-cell lymphoma of high-risk adults; its toxicity is acceptable. However, on the R-DA-EPOCH-21 therapy, the results of therapy are unsatisfactory. The R-DA-EPOCH-21 protocol with auto-HSCT was more effective than without auto-HSCT, however, due to the small number of patients, the results were unpresentative. The results of therapy according R-mNHL-BFM-90 protocol with auto-HSCT and without auto-HSCT were not differ.
- Open Access
- 25 November 2024
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 69 (3) , 368-383
Biopsy-free diagnosis of primary diffuse large B-cell lymphoma of the central nervous system
Introduction. The use of invasive methods for diagnosing primary diffuse large B-cell lymphoma of the central nervous system (PDLBCL CNS) and primary vitreoretinal lymphoma (PVRL) is often associated with the development of severe neurological deficits and disability of patients. A promising direction in the diagnosis of PDLBCL CNS and PVRL is the use of non-invasive approaches based on molecular genetic methods for the determination of mutations in the MYD88 gene in the cerebrospinal fluid (CSF), vitreous fluid (VF) and free circulating tumor DNA (cfDNA) in blood serum.Aim: to present the potential of non-invasive diagnosis of PDLBCL CNS and PVRL.Main findings. The study included 6 patients (4 — PDLBCL CNS, 2 — PVRL). The average age was 64 (54–75) years. Despite increased cytosis in the CSF in all 4 patients with PDLBCL CNS, the tumor population was determined by flow cytometry in only half of the cases. According to a molecular genetic study, mutations in the MYD88 gene with an allelic load from 2.5% to 15% were detected in the genomic DNA of the CSF of all patients. In 2 patients with PVRL, mutations in the MYD88 gene were detected in VF with an allelic load of 4.2% and 6.6%, which was the only confirmation of the diagnosis. Currently, 5 patients have completed the treatment program and 1 is undergoing therapy. All 5 patients are in complete remission (CR) of the disease with follow-up periods from 1 to 8 months.
- 25 November 2024
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 69 (3) , 368-383
Open AccessBiopsy-free diagnosis of primary diffuse large B-cell lymphoma of the central nervous system
Introduction. The use of invasive methods for diagnosing primary diffuse large B-cell lymphoma of the central nervous system (PDLBCL CNS) and primary vitreoretinal lymphoma (PVRL) is often associated with the development of severe neurological deficits and disability of patients. A promising direction in the diagnosis of PDLBCL CNS and PVRL is the use of non-invasive approaches based on molecular genetic methods for the determination of mutations in the MYD88 gene in the cerebrospinal fluid (CSF), vitreous fluid (VF) and free circulating tumor DNA (cfDNA) in blood serum.Aim: to present the potential of non-invasive diagnosis of PDLBCL CNS and PVRL.Main findings. The study included 6 patients (4 — PDLBCL CNS, 2 — PVRL). The average age was 64 (54–75) years. Despite increased cytosis in the CSF in all 4 patients with PDLBCL CNS, the tumor population was determined by flow cytometry in only half of the cases. According to a molecular genetic study, mutations in the MYD88 gene with an allelic load from 2.5% to 15% were detected in the genomic DNA of the CSF of all patients. In 2 patients with PVRL, mutations in the MYD88 gene were detected in VF with an allelic load of 4.2% and 6.6%, which was the only confirmation of the diagnosis. Currently, 5 patients have completed the treatment program and 1 is undergoing therapy. All 5 patients are in complete remission (CR) of the disease with follow-up periods from 1 to 8 months.
- Open Access
- 14 June 2024
- Published by Publishing House ABV Press in MD-Onco
- Vol. 4 (2) , 65-70
Acute promyelocytic leukemia presenting with basophilia: diagnostic features and clinical observation
Acute promyelocytic leukemia (APL) is a blood tumor characterized by aggressive clinical progression with characteristic clinical and laboratory signs (typical tumor cell morphology, severe hemorrhagic syndrome, hemorrhages with hematoma formation, excessive fibrinolysis, disseminated intravascular coagulation syndrome) but modern approaches to therapy potentially make this disease fully curable. APL is considered one of the most studied subtypes of acute leukemia and is characterized by abnormal proliferation of promyelocytes in the bone marrow. The morphologic picture of APL is quite diverse, but an increased basophil count represents a rare manifestation that requires further study and understanding of its significance. Currently, there are limited scientific data on the clinical course and response to standard therapy in patients with APL presenting with basophilia.
- 14 June 2024
- Published by Publishing House ABV Press in MD-Onco
- Vol. 4 (2) , 65-70
Open AccessAcute promyelocytic leukemia presenting with basophilia: diagnostic features and clinical observation
Acute promyelocytic leukemia (APL) is a blood tumor characterized by aggressive clinical progression with characteristic clinical and laboratory signs (typical tumor cell morphology, severe hemorrhagic syndrome, hemorrhages with hematoma formation, excessive fibrinolysis, disseminated intravascular coagulation syndrome) but modern approaches to therapy potentially make this disease fully curable. APL is considered one of the most studied subtypes of acute leukemia and is characterized by abnormal proliferation of promyelocytes in the bone marrow. The morphologic picture of APL is quite diverse, but an increased basophil count represents a rare manifestation that requires further study and understanding of its significance. Currently, there are limited scientific data on the clinical course and response to standard therapy in patients with APL presenting with basophilia.
- Open Access
- 2 April 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (2) , 14-25
Significance of immunophenotypic, cytogenetic, and molecular markers in adult patients with T-cell lymphoblastic leukemia
Background. Current chemotherapy protocols for T-cell acute lymphoblastic leukemia (T-ALL) allow achieving a 5-year overall survival of 60–90 %, but relapsed and refractory forms remain incurable situations.Aim. To determine the significance of immunophenotypic, cytogenetic and molecular markers in adult T-ALL patients receiving therapy according to the ALL-2016 protocol.Materials and methods. From December 2016 to June 2022, 113 patients with primary T-ALL were included in the study. Cytogenetic study was performed in 104 (92 %) patients; anomalies in the IKZF1 and NOTCH1 genes were investigated in 43 (38 %) patients.Results. The worst prognosis was in patients with ETP and near-ETP variants of T-ALL (3-year disease-free survival was 54 % in ETP group, 33 % in near-ETP group vs TI/II – 79 %, TIII – 89 %, TIV – 75 %). In early T-ALL variants, abnormal karyotype was most common (ETP – 80.7 %, near-ETP – 60 %). Aberrations in NOTCH1 gene were found in 53 % of cases (in 23 out of 43 patients), and no mutations were found in IKZF1 gene in our study. In the group with no NOTCH1 abnormalities, the overall survival was significantly worse than in the group with abnormalities (NOTCH1– – 52 % vs NOTCH1+ –81 %; p = 0.05).
- 2 April 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (2) , 14-25
Open AccessSignificance of immunophenotypic, cytogenetic, and molecular markers in adult patients with T-cell lymphoblastic leukemia
Background. Current chemotherapy protocols for T-cell acute lymphoblastic leukemia (T-ALL) allow achieving a 5-year overall survival of 60–90 %, but relapsed and refractory forms remain incurable situations.Aim. To determine the significance of immunophenotypic, cytogenetic and molecular markers in adult T-ALL patients receiving therapy according to the ALL-2016 protocol.Materials and methods. From December 2016 to June 2022, 113 patients with primary T-ALL were included in the study. Cytogenetic study was performed in 104 (92 %) patients; anomalies in the IKZF1 and NOTCH1 genes were investigated in 43 (38 %) patients.Results. The worst prognosis was in patients with ETP and near-ETP variants of T-ALL (3-year disease-free survival was 54 % in ETP group, 33 % in near-ETP group vs TI/II – 79 %, TIII – 89 %, TIV – 75 %). In early T-ALL variants, abnormal karyotype was most common (ETP – 80.7 %, near-ETP – 60 %). Aberrations in NOTCH1 gene were found in 53 % of cases (in 23 out of 43 patients), and no mutations were found in IKZF1 gene in our study. In the group with no NOTCH1 abnormalities, the overall survival was significantly worse than in the group with abnormalities (NOTCH1– – 52 % vs NOTCH1+ –81 %; p = 0.05).